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Abstract 
Aim: Suppressor of Cytokine Signaling 3 (SOCS3) gene belongs to SOCS family as one of the negative regulators of 
cytokine signaling and IFN response that function via the JAK-STAT pathway in antiviral response. SOCS3 expression 
and genetic polymorphism influences the pathogenesis and outcome of antiviral treatment in hepatitis C virus (HCV) 
infected patients. This study was designed for analysis of SOCS3 gene expression and polymorphism in Pakistani HCV 
patients.
Methods: This descriptive study was conducted on 250 diagnosed HCV genotype 3a infected subjects. The study 
population was divided into two major groups on the basis of therapeutic response i.e. sustained virological response 
(SVR) and non-responders/relapsers (NR). SOCS3 gene mRNA expression analysis was done by using Real time 
PCR technique, whereas ARMS PCR technique was used for analysis of SOCS3 gene polymorphisms i.e. 8464 A/C 
(rs12952093), −4874 A/G (rs4969170) and −1383 A/G, (rs4969168).
Results: Gene expression analysis of SOCS3 showed that there was statistically significant increase of 2.275-fold 
and 3.72-fold in relative gene expression for SVR and NR as compared to normal healthy samples (p < 0.001). The 
distribution of rs4969168, rs4969170 and rs12952093 genotype frequencies between SVR versus NR group were not 
statistically significant, only the allelic frequency of rs4969170 was statistically significant (p ≤ 0.0001) with therapeutic 
response.
Conclusion: The gene expression analysis of SOCS3 showed a clear difference in mRNA expression of SOCS3 as a 
possible indicator of therapeutic response rather than polymorphism of SOCS3 gene in our studied population.
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Background
Cytokines including interleukins, interferons (IFNs i.e. 
IFN-α, IFN-β, and IFN-ω) and hemopoietins activate a 
potent positive feedback mechanism which produces 
high concentrations of IFNs locally after viral infection. 
IFNs bind to IFN receptors to activate JAK-STAT sign-
aling pathway which transmits information to cause 
transcription of genes in response to infection (Fallahi 
et al. 2012; Stevenson et al. 2013). There are a number of 
negative regulators i.e. SOCS, USP18, PIAS and TcPTP 
which control the IFN signaling. Suppressor of cytokine 
signaling (SOCS) proteins, an important negative regu-
lators of JAK-STAT signaling, consists of eight mem-
bers SOCS1 to SOCS7 and the cytokine-inducible Src 
homology 2 domain-containing protein (CIS) (Luedde 
et al. 2001). Out of these, SOCS3 strongly interacts with 
activated cytokine receptors such as gp130, to negatively 
regulate STAT3 phosphorylation via kinase inhibitory 
region (KIR) in its N-terminal domain (Seki et al. 2008). 
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SOCS3 simultaneously binds to cytokine receptors and 
JAK1, JAK2, and TYK2 (but not JAK3), and inhibits the 
catalytic domain of the kinases (Babon et al. 2012).
Hepatitis C virus (HCV), a major cause of acute or 
chronic liver disease, is a non-cytopathic hepatic virus 
which interacts with the host immune system in a com-
plex way. During a primary infection, there is a rapid 
increase in HCV RNA level in first few days and remains 
high throughout the incubation period i.e. 10–12 weeks 
(Thimme et al. 2001). Worldwide more than 170 million 
people are infected with this virus, whereas in Pakistan, 
approximately 10 million people are infected with HCV 
(Anwar et  al. 2013; Rana et  al. 2013). Standard therapy 
against HCV is a combination of immune modulator 
plus an antiviral agent [Pegylated interferon α (PEG-
IFN-α) and guanosine analog ribavirin], which predicts 
only a 50  % sustained virologic response (SVR; if HCV 
RNA remain undetectable at 6  months post treatment 
completion), depending upon HCV infected genotype 
(Tsubota et  al. 2011). HCV genotype 3, most prevalent 
type in Pakistan, had been considered a good responsive 
genotype against standard treatment. But recent stud-
ies reported it as a difficult to treat genotype both in 
traditional and direct acting antivirals (DAA) treatment 
(Ampuero and Romero-Gomez 2015). Besides being 
expensive in a country like Pakistan HCV treatment has 
many potential severe side effects so several attempts 
are being in process to predict a successful therapeutic 
outcome.
HCV has been reported to reduce SOCS1 expression 
and up-regulate SOCS3 expression to facilitate HCV rep-
lication (Miyoshi et al. 2005; Collins et al. 2014). Recently, 
Shao et  al. (2010, 2013) reported that overexpression of 
SOCS3 suppress HCV replication in vitro in an mTOR-
dependent manner, and SOCS1 promotes HCV replica-
tion by blocking the anti-viral activity of IFN, suggesting 
that both proteins i.e. SOCS1 and SOCS3 act via alter-
native mechanisms regarding regulation of IFN activ-
ity. HCV core and NS5a proteins interacts with SOCS3 
resulting in impaired IFN signaling (Miyoshi et al. 2005). 
This complex mechanism employed by HCV in rela-
tion to SOCS gene might represent a crucial step in 
HCV infection and pathogenesis, including suppressed 
inflammation and even hepatocellular cancer progres-
sion. In vitro studies have demonstrated that a high level 
of SOCS3 expression was found in HCV-replicating cells 
which were resistant to IFN therapy (Persico et al. 2007). 
Recent in vivo studies have demonstrated a positive cor-
relation between high pretreatment SOCS3 gene expres-
sion and nonresponse to therapy in genotype 1-infected 
patients both in the liver as well as in peripheral blood 
mononuclear cells (PBMCs) (Walsh et  al. 2006; Persico 
et al. 2008; Kim et al. 2009).
Persico et  al. (2008) studied three SOCS3 genetic 
polymorphisms, 1383 A/G, (rs4969168), −4874 A/G 
(rs4969170) and −8464 A/C (rs12952093) and reported 
that these genetic polymorphisms in chronic hepati-
tis C regulate the expression of SOCS3 and interferon 
treatment outcome. Among these variants, rs4969168 
is known as the transcriptional regulator of the gene 
whereas information regarding the function other two 
polymorphisms is not yet defined, but are considered to 
be linked with SOCs3 expression. Out of these SOCS3 
polymorphisms AA genotype of rs4969170 is strongly 
associated with antiviral therapy in HCV patients that 
might be associated with high expression of hepatic 
SOCS3 (Persico et al. 2008; Kim et al. 2009). In a recent 
report, Angelo et al. (2013) studied that combination of 
MxA, OPN and SOCS3 protective genotypes was more 
frequent among the SVR patients. The combined analysis 
of SOCS3 and IL28B protective genotypes (G/G + C/C) 
had greater power than IL28B to predict SVR. The G/G 
genotype was more generally detected in the sustained 
virological responders, whereas the A/G + A/A genotype 
was more frequent in NR/R subjects (Angelo et al. 2013). 
However, Hamdi et al. (2012) reported no significant dif-
ference in SOCS3 gene expression between responders 
and non-responders in HCV-genotype 4 patients. Simi-
lar to SOCS3 other genes such as STAT3 are also found 
to be associated with HCV infection. Expression lev-
els of STAT3 are found to be reduced in HCV-infected 
patients, Huh-7 cells transfected with HCV constructs 
and also in HCV-infected liver tissue samples (Stevenson 
et al. 2013; Li et al. 2012). The expression of STAT3 along 
with SOCS3 has been recently found to be associated 
with IFN treatment in HCV infection and HCV-infected 
cell line (Ryan et al. 2012; Zhao et al. 2016).
To the best of our knowledge it is the first study con-
ducted in Pakistan relating SOCS3 and STAT3 expres-
sion and SOCS3 SNP profiling in HCV infected patients 
aimed with the prediction of therapeutic outcome in 
HCV patients in our population.
Methods
Patients cohort
All (250) HCV infected participants were recruited from 
outdoor patient (OPD) Department of Gasteroenterol-
ogy, Jinnah Hospital Lahore and Department of Gas-
troenterology and Hepatology, Sheikh Zayed Hospital, 
Lahore during Oct-2013 to April 2015. The study proto-
col was approved from the Institutional Ethical Review 
Committee, and Advance Studies and Research Board, 
University of Health Sciences Lahore. An informed writ-
ten consent was obtained with all the relevant details 
such as age, gender, clinical findings, duration of disease 
and therapeutic history in a structured questionnaire. An 
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approximately, 6  ml of blood sample was collected for 
RNA and DNA isolation. Healthy volunteers (100) were 
also recruited in the current study after informed consent 
and clinical testing of HCV, HBV and any other disease.
The inclusion criteria for the study was as follows: indi-
viduals age ≥18  years of either gender, diagnosed HCV 
genotype 3a patients (Both ELISA and PCR positive) with 
Peg IFN plus ribavirin treatment and on relapse of HCV 
infection after the completion of therapy were included. 
Patients were excluded if they were positive for HBV or 
any other known viral infection, any type of liver dis-
eases, malignancy i.e. HCC and others. These patients 
were divided into two groups depending upon the treat-
ment response i.e. Sustained virological response (SVR) 
and non-responders/relapse (NR). SVR: is defined as an 
undetectable serum HCV after 6  months of combina-
tion therapy. NR: is defined as a detectable serum HCV 
level after 6 month of combination therapy or a virologi-
cal relapse occurs when HCV RNA reappears in a patient 
who had completed the treatment with negative HCV 
RNA as an indicator of end-of-treatment response.
SOCS3 and STAT3 gene expression analysis
To evaluate the effect of SOCS3 and STAT3 gene expres-
sion in HCV infected patients with different therapeutic 
response, total RNA was extracted from the blood sam-
ple of HCV patients and normal (healthy) volunteers fol-
lowed by gene expression analysis. Due to problems in 
sample collection from all the patients at different time 
intervals, the RNA used for the Real Time PCR analysis 
consists of samples taken before start of therapy (later on 
designated as SVR or NR group) and from patients who 
already had a relapse of disease after completion of com-
bination therapy. Briefly, mRNA expression of SOCS3 
and STAT3 gene was carried out after RNA extrac-
tion from freshly collected blood samples after isolating 
peripheral blood mononuclear cells (PBMCs). Total cel-
lular RNA was extracted from PBMCs using the TriZol 
reagent (Invitrogen, USA) following the manufactur-
er’s instructions. Total cellular RNA (1  μg) was reverse 
transcribed into single-stranded complementary DNA 
(cDNA) using first strand cDNA synthesis kit (Thermo 
scientific, USA). The mRNA expression level of SOCS3 
and STAT3 gene as well as GAPDH, a housekeeping 
gene used as internal control for normalization (Primer 
sequences in Table 1), was detected on iQ5 icycler Real 
Time PCR detection system (Biorad, USA). Each reaction 
on Real Time PCR was performed in triplicate. The rela-
tive gene expression analysis was done by using iQ5 2.1 
software. Results obtained were analyzed statistically for 
relative gene expression changes by student’s t test and 
one-way ANOVA where p < 0.05 was considered as sta-
tistically significant.
Genotyping of SOCS3 gene
Three SOCS3 gene polymorphisms i.e. −8464 A/C 
(rs12952093), −4874 A/G (rs4969170) and 1383 A/G 
(rs4969168) were chosen for genotyping. Genomic DNA 
was extracted from PBMCs of samples using standard 
Phenol–Chloroform method. The extracted DNA was 
subjected to genotyping using amplification refractory 
mutation system-polymerase chain reaction (ARMS-
PCR) of SOCS3 specific regions spanning the polymor-
phic sites. For each assessed polymorphism, the assay 
included tetra-primer pair (Table 1). ARMS-PCR ampli-
fications were carried out in 15  µl reaction mixtures 
consisting of 1 µl of diluted DNA (50 ng/µl), 10 × PCR 
buffer, 2.5  mM MgCl2, 0.4  µl of mixture containing 
100 µM of each dNTP, 0.2 mM of inner primers, 0.4 mM 
of outer primer and 1U (unit) of Taq DNA polymerase 
(Thermo scientific, USA). Temperature profile consisted 
of an initial denaturation at 94 °C for 4 min followed by 
35 cycles of denaturation at 94  °C for 30 s, annealing at 
62 (rs12952093 and rs4969170) and 64 °C (rs4969168) for 
30 s and extension at 72 °C for 40 s. and a final extension 
step at 72 °C for 5 min.
Statistical analysis
Genotype and allele frequency for the SNPs was calcu-
lated by the Online Genetic Epidemiology tool OEGE 
(http://www.oege.org). Same software was used to asses 
Hardy–Weinberg equilibrium using the Pearson good-
ness-of-fit χ2 test with 1° of freedom for biallelic mark-
ers. For other variables mean  ±  SD was calculated for 
quantitative variables. On the contrary, qualitative vari-
ables were expressed as frequencies and percentages. 
Chi square test was applied to measure the association 
of general characteristics among the study groups while 
One-way ANOVA was used to compare the mean of 
quantitative parameters among the study group. In order 
to evaluate the association of polymorphism with the 
study groups’ four genetic models (Co-dominant Model, 
Dominant Model, Recessive Model and Allele Model) 
were constructed. Crude and adjusted Odds ratios (ORs) 
with their 95  % confidence intervals (CI) of the asso-
ciation of polymorphism with the study groups was esti-
mated by the logistic regression. For adjusted ORs and 
95 % CI adjustment was made by potential confounders 
such as age, gender and viral titer. All the data analysis 
was performed by IBM SPSS ver. 21 while p value <0.05 
was considered as statistically significant.
Results
Patient characteristics
It was a descriptive study with follow-up to determine 
the response of the subject against PEG-IFNα plus riba-
virin therapy, periodic follow-up of each patient was 
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made till June, 2015. Out of total 250 participants, 69 
patients discontinued the therapy because of side effects 
and financial constraints, whereas 40 patients were lost 
to follow-up (Fig. 1). A total of 141 eligible patients who 
completed the Peg-IFN-α plus ribavirin therapy, with 
viral titer of ~104–107 IU/ml at the time of diagnosis were 
screened for further analysis. After completion of treat-
ment 115 patients achieved SVR (82.6 %) and 26 patients 
either were non-responders or had a relapse of disease. 
HCV infected patients with SVR and NR were compared 
for gender, age, ALT, AST and viral titre. The categoriza-
tion of male patients on the therapeutic response showed 
that 77.6 % achieved SVR, whereas 87.5 % females showed 
SVR. Almost a double number of males (22.4  % out of 
total male patients) showed a relapse after treatment as 
compared to female patients (12.5  % out of total male 
patients) but overall the difference of gender was not sta-
tistically significant with therapeutic response (p = 0.37). 
The overall mean age in all patients was 40.79 ± 9.8 while 
relapse patients had high mean age 43.58 ± 11.6 with p 
value 0.0344. In case of ALT and AST overall mean ± SD 
was 92.22  ±  71.5 and 104.96  ±  82.9, NR had high-
est mean  ±  SD of ALT and AST i.e. 203.27  ±  7.2 and 
229.31 ± 92.1 than SVR (p = 0.0001). Similarly, bilirubin 
concentration was significantly associated in SVR and NR 
group i.e. 23.2 ± 7.32 and 27.2 ± 10.98 with p = 0.024. 
HOMA-IR of the HCV patients was also calculated, but 
no significant difference was observed between both 
groups (p = 0.45; Table 2).
Expression analysis of SOCS3 and STAT3 gene
To evaluate the effect of SOCS3 gene expression, known 
to suppress antiviral activity via the IFN signaling path-
way, in HCV infected patients with different therapeu-
tic response, total RNA was extracted from the blood of 
HCV patients and normal (healthy) volunteers followed 
by gene expression analysis. Considering the baseline 
expression level of SOCS3 in healthy controls as 1.0, a 
statistically significant (p < 0.001) up-regulation of rela-
tive gene expression of 2.27 ± 1.18 and 3.72 ± 1.08 folds 
was observed in SVR and NR group of patients respec-
tively. Moreover, the difference between healthy con-
trols versus SVR, healthy control versus NR and SVR 
versus NR was also found to be statistically significant 
i.e. p = 0.0021, p = 0.0001, and p = 0.0029 respectively. 
Overall, the difference in SOCS3 gene expression in this 
study was found to be associated with the response to 
combination therapy (p < 0.0001; Fig. 2).
Similarly, STAT3 gene expression was studied in HCV 
patients and normal (healthy) volunteers. Considering 
the baseline expression level of STAT3 in healthy controls 
as 1.0, a statistically significant (p = 0.012) up-regulation 
of relative gene expression of 1.28 ±  0.29 was observed 
in SVR group, whereas down-regulation of expression i.e. 
0.89 ± 0.43 folds was observed in NR group of patients 
(p = 0.49) in comparison with healthy controls. Moreo-
ver, the difference of expression levels between SVR ver-
sus NR was also found to be statistically significant i.e. 
p = 0.028 (Fig. 3).
Table 1 Sequences of primers for PCR amplification
No Gene Primer Product size
1. rs12952093-1 AACACTTGTTTTTTGTTTGACACAGTACCC Common amplicon = 449 bp
C allele = 204 bp
A allele = 294 bprs12952093-2 CACTCCAGCCTGGGCAACAAAT
rs12952093-3 CTCCCCCGATAATTGCAAACAAAAT
rs12952093-4 AACATGGCAAACACCGTCTCTACCT
2. rs4969170-1 TCTTTCCATTGTTTTTAGAGACCCCA Common amplicon = 375 bp
G allele = 235 bp
A allele = 196 bprs4969170-2 AACCAAAAAGTACTCTAGAAGAAAGCATGC
rs4969170-3 AAAGACGGAAAAAGGCAGACACTCT
rs4969170-4 CCACATTTTCAGAAACGTTTTCGTC
3. rs4969168-1 AGACCAGCTGACCAGCCCATACA Common amplicon = 211 bp
A allele = 120 bp
G allele = 138 bprs4969168-2 GGGGAAGCAACATTTGGAGGGTAC
rs4969168-3 ACCAGGAGCCTGAGGTGAAAGATGT
rs4969168-4 GACAGTCACCGAAAACACAGGTTCC
4. SOCS3-F GGAGACTTCGATTCGGGACC 131 bp
SOCS3-R GAAACTTGCTGTGGGTGACC
5. STAT3-F GGCATTCGGAAAGTATTGTCG 265 bp
STAT3-R GGTAGGCGCCTCAGTCGTATC
6. GAPDH-F ACCACAGTCCATGCCATCAC 453 bp
GAPDH-R TCCACCACCCTGTTGCTGTA
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Genotypes frequencies of SOCs3 polymorphism and their 
association with SVR and NR in HCV patients
The population was tested for HWE for SOCs3 polymor-
phisms, healthy volunteers were in HWE for all three 
polymorphisms under study. SOCS3 polymorphism 
rs4969170 and rs12952093 were in HWE among the 
individuals belonging to SVR group (p < 0.0001, but only 
rs12952093 was in HWE among the individuals of NR 
group (p < 0.0001). SOCS3 polymorphism rs4969168 was 
not in HWE among both groups i.e. SVR and NR. Link-
age disequilibrium analysis showed that all SNPs under 
study were weekly associated with HCV infected groups.
 In order to evaluate the association of polymorphisms 
rs4969168, rs4969170 and rs12952093 with study popu-
lation, three genetic models (co-dominant, recessive, and 
dominant) were constructed with crude and adjusted 
ORs with 95  % CI. After the statistical analysis the 
results of all three SNPs i.e. the genotype distributions 
and association between overall treatment responses are 
shown in Table  3. There were no significant difference 
in the genotype or allele distribution of rs4969168 G/A 
and rs12952093 C/A in any studied model with p > 0.05 
before and after adjusted OR. Distribution of rs4969170 
A/G genotype also showed no significant association 
Fig. 1 Flow chart depicting the sample size of HCV patients enrolled in the study and response rate to treatment
Table 2 Demographic and clinical characteristics of HCV infected patients with different therapeutic response
* p ≤ 0.05 statistically significant
a Data only available for 87 patients
Overall mean/median SVR mean/median Non-responders/relapser mean/median p value
Gender (n,  %)
 Male 85 (60.2 %) 66 (77.6 %) 19 (22.3 %) 0.317
 Female 56 (39.7 %) 49 (87.5 %) 7 (12.5 %)
Body mass index (kg/m2) 22.43 ± 4.3 22.31 ± 3.5 22.98 ± 7.2 0.48
Age (years) 40.0 ± 9.5 39.2 ± 8.9 43.58 ± 11.6 0.0344
ALT (IU/ml) 90.9 ± 65.5 64.5 ± 41 203.27 ± 7.2 0.0001
AST (IU/ml) 102.34 ± 84.1 73.64 ± 48.3 229.31 ± 92.1 0.0001
Albumin (g/l) 40.95 ± 10.56 41.23 ± 10.98 39.76 ± 8.54 0.52
Total Bilirubin (mg/dl) 23.93 ± 8.22 23.2 ± 7.32 27.2 ± 10.98 0.024
Fasting serum glucose (mg/l)a 95 (82–99) 94 (83–99) 96 (82–99) 0.84
Fasting insulin (μU/ml)a 6.5 (3–9) 6 (3–9) 7 (4–4.7) 0.43
HOMA-IRa 1.29 (0.74–3.25) 1.12 (0.74–2.11) 1.46 (0.77–3.25) 0.45
Viral titer (IU/ml)
 <100,000 68 56 12 0.706
 >100,000 73 59 14
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with response in both groups, whereas the allele model 
showed that about 28.8  % of the patients with NR had 
effecting allele while in SVR its frequency was 64.3  % 
which was statistically significant p ≤ 0.0001 with much 
greater OR as compared to others (p < 0.0001).
Discussion
A major goal of medical genetics during the last two dec-
ades has been to unravel the influence of host’s genetics 
on susceptibility or pathogenesis of common diseases and 
to find association of human genetic variations with these 
diseases. Variation in genes which are especially associ-
ated with the antiviral pathways influence the response to 
viral attack, antiviral agents and ultimately the outcome 
of diseases. Gossens and Nagro (2014) reported that in 
genotype 3 patients the predictive factors/markers for 
relapse include male gender (16 vs. 7 %), old age >55 years 
(27 vs. 12  %), high viral load (20 vs. 7  %) and advanced 
fibrosis stage (20 vs. 6 %). Recently, Aziz et al. (2016) in 
a multivariate logistic regression analysis on patients 
receiving combination therapy from Pakistan reported 
that 74.8 % patients showed SVR whereas 25.2 % patients 
were virologicaly non-responders, showing detectable 
HCV RNA at the end of treatment. The data regarding 
non-response/relapse to combination therapy in Aziz 
et  al. (2016) study is similar to the results of current 
study where the relapse rate is 18.4 % and almost a dou-
ble number of males (22.4  % out of total male patients) 
showed a relapse after treatment as compared to female 
patients (12.5 % out of total male patients) but overall the 
difference of gender was not statistically significant with 
therapeutic response (p = 0.37) in the current study.
Changes in immune system occurs with increase in age 
that leads to poor responsiveness to new antigen due to 
decrease of naïve T cell, less capacity to produce inter-
leukin, changes in cytokine profile, deficiency in T-cell 
receptor signal transduction and activation (Pawelec 
et  al. 2001; Timm and Thoman 1999). The mean age 
in SVR and relapse patients in the current study were 
39.2  ±  8.96 and 43.58  ±  11.6 indicating a significant 
association with treatment response (p =  0.0344). Aziz 
et  al. (2016) studied correlation between pretreatment 
viral load, ALT, AST and SVR and observed HCV RNA 
level (p  <  0.0001), ALT level at the time of treatment 
(p  >  0.003), and steatosis (Non-Fatty liver, p  <  0.005) 
and found a significant association with treatment suc-
cess. Similarly, in the current study the levels of AST 
and ALT at the start of treatment were high in NR group 
(p  =  0.0001), but no significant difference in viral load 
(p = 0.706) was observed.
Recent in  vivo studies have demonstrated a positive 
correlation between high pretreatment SOCS3 gene 
expression and nonresponse to therapy in genotype-1 
infected patients both in the liver as well as in PBMCs 
(Walsh et  al. 2006; Persico et  al. 2008; Kim et  al. 2009). 
In the present study, the overall pretreatment SOCS3 
mRNA level was higher in patients than in healthy con-
trols (p < 0.001) and this could be explained by the previ-
ously reported role of SOCS3 in the negative regulation 
of the JAK-STAT pathway (Persico et  al. 2007, 2008; 
Kim et  al. 2009; Krebs and Hilton 2001). In the present 
study, a statistically significant increase in pretreatment 
expression of SOCS3 was observed in SVR versus NR 
(p = 0.002). The increase in pretreatment SOCS3 mRNA 
level in HCV genotype 3 infected patients (SVR and 
NR) as compared to healthy control is in support of the 
Fig. 2 SOCS3 gene expression in PBMCs from healthy volunteers and 
HCV patients (SVR and NR group) prior to the initiation of PEG-IFNα 
and ribavirin treatment. p value ≤0.05 was considered as statistically 
significant
Fig. 3 STAT3 gene expression in PBMCs from healthy volunteers and 
HCV patients (SVR and NR group) prior to the initiation of PEG-IFNα 
and ribavirin treatment. p value ≤0.05 was considered as statistically 
significant
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hypothesis that the increase in SOCS3 and resistance to 
therapy could be HCV genotype dependent. This obser-
vation is also in agreement with the recent findings that 
SOCS3 expression level induced by HCV infection is 
higher in genotype 1 as compared to genotype 2 (Persico 
et al. 2007; Kim et al. 2009).
The results of current study are in accordance with the 
earlier studies on genotype 1 (Persico et  al. 2007, 2008; 
Walsh et  al. 2006; Kim et  al. 2009) but are in concord-
ance with the study of Jablonowska et  al. (2014) who 
observed higher pretreatment hepatic SOCS3 mRNA 
expression in responders than in non-responders in 
genotype 4 patients. Similarly, Pascarella et  al. (2013) 
observed no significant association of expression of 
SOCS genes (SOCS1, 3 and 7) and prediction of virologi-
cal response in genotype 3 patients. Jablonowska et  al. 
(2014) suggested that this discrepancy in results could 
be explained by a genetic variability in SOCS3 since a 
genetic polymorphism in the SOCS3 gene was reported 
to influence the level of SOCS3 expression and IFN 
Table 3 Distribution of alleles and genotype frequencies and comparison in HCV patients
OR odd ratio, CI confidence interval, NA not applicable
* Adjusted on the basis of age, gender, and viral titer. p ≤ 0.05 statistically significant
Non-relapsers n (%) Relapser n (%) OR crude (95 % CI) p value OR Adjusted* (95 % CI) p value adjusted*
SOCS3 rs4969168 (G/A) model
Genotype
Co-dominant GG 61 (53.0) 12 (46.2) – 0.759 – –
GA 44 (38.3) 12 (46.2) 1.386 (0.570–3.373) 0.471 1.242 (0.498–3.100) 0.642
AA 10 (8.7) 2 (7.7) 1.017 (0.197–5.238) 0.984 0.872 (0.163–4.658) 0.873
Recessive GG and GA 105 (91.3) 24 (92.3) 0.875 (0.180–4.255) 0.868 0.784 (0.156–3.928) 0.767
AA 10 (8.7) 2 (7.7)
Dominant GG 61 (53.0) 12 (50.0) 1.318 (0.561–3.095) 0.868 1.173 (0.487–2.828) 0.722
GA and AA 54 (47.0) 14 (50.0)
Alleles
G 166 (72.7) 36 (69.2) 0.8675 (0.450 –1.671) 0.6709 0.8675 (0.4503–1.6712) 0.6709
A 64 (27.8) 16 (30.7)
SOCS3 rs4969170(A/G) model
Genotype
Co-dominant AA 25 (21.7) 3 (11.5) – 0.473 – –
AG 32 (27.8) 9 (34.6) 2.344 (0.574–9.576) 0.236 1.951 (0.456–8.346) 0.367
GG 58 (50.4) 14 (53.8) 2.011 (0.531–7.622) 0.304 1.698 (0.427–6.756) 0.452
Recessive AA and AG 57 (49.6) 12 (46.2) 2.130 (0.591–7.676) 0.753 1.069 (0.445–2.568) 0.881
GG 58 (50.4) 14 (53.8)
Dominant AA 25 (21.7) 3 (11.5) 1.147 (0.488–2.691) 0.239 1.790 (0.473–6.768) 0.391
AG and GG 90 (78.3) 23 (88.5)
Alleles
A 82 (35.6) 37 (71.1) 4.452 (2.306 –8.595) <0.0001 4.452 (2.3060–8.595) <0.0001
G 148 (64.3) 15 (28.8)
SOCS3 rs12952093(C/A) model
Genotype
Co-dominant CC 22 (19.1) 4 (15.4) – 0.905 – –
CA 25 (21.7) 6 (23.1) 1.320 (0.329–5.293) 0.695 1.564 (0.377–6.489) 0.538
AA 68 (59.1) 16 (61.5) 1.294 (0.391 –4.282) 0.673 1.374 (0.401–4.705) 0.613
Recessive CC and CA 47 (40.9) 10 (38.5) 1.106 (0.462–2.648) 0.821 1.076 (0.433–2.673) 0.875
AA 68 (59.1) 16 (61.5)
Dominant CC 22 (19.1) 4 (15.4) 1.301 (0.407–4.160) 0.656 1.425 (0.433–4.686) 0.560
CA and AA 93 (80.9) 22 (84.6)
Alleles
C 69 (30.0) 14 (26.9) 0.859 (0.437–1.687) 0.660 0.859 (0.437–1.687) 0.660
A 161 (70.0) 38 (73.0)
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treatment outcome in chronic hepatitis C (Persico et al. 
2008). Persico et al. (2008) studied three SOCS3 genetic 
polymorphisms, −8464 A/C (rs12952093), −4874 A/G 
(rs4969170) and 1383 A/G (rs4969168), and reported sig-
nificant differences in their effects on outcome of antivi-
ral therapy. Particularly, SOCS3 (−4874 AA) genotypes 
express SOCS3 at elevated levels and consequently have 
a poorer response to therapy (Persico et  al. 2007, 2008; 
Funaoka et  al. 2011). Based on recent findings, the pre-
sent study aimed to investigate the role of SOCS3 gene 
polymorphism in resistance to therapy in HCV genotype 
3 infected patients since no data concerning this geno-
type have been reported yet.
In the current study rs4969168 genotypes (GG, GA and 
AA) and allele frequency (G/A) when compared in SVR 
versus NR the results were not statistically significant in 
any model (p = 0.647, p = 0.767 and p = 0.722; Table 3). 
These findings are in agreement with Persico et al. (2008) 
who studied that the rs4969168 genotypes were not sig-
nificantly associated with antiviral therapy where GG 
genotype was most frequent in both groups with 64.2 % 
patients in NR and 68.5 % patients in SVR group. In cur-
rent study, these findings can also be explained by the 
lack of HWE in the sample population.
Smilarly, rs4969170 genotype (AA, AG, GG) and allele 
frequency (G, A) distribution was not statistically differ-
ent between SVR versus NR group of patients (p = 0.367, 
p = 0.881, p = 0.391 for genotypes and p = 0.67 for allele; 
Table  3). The results are in concordance with Persico 
et  al. (2008) and Angelo et  al. (2013) who studied that 
rs4969170 AA genotype is strongly associated with failure 
of the antiviral IFNα therapy in HCV genotype 1 infected 
patients, the reason of this concordance with current 
study could be due to the difference in HCV infected 
genotype i.e. HCV genotype 3a which is now considered 
as a difficult to treat genotype. However, in the current 
study a statistically significant association of rs4969170 
(A/G) allele frequency with therapeutic response was 
observed in SVR vs NR groups (p ≤ 0.0001). Angelo et al. 
2013 studied that rs4969170 GG genotype frequency 
was much higher in the SVR patients than in the non-
responders/relapse patients.
SOCS3 gene SNP rs12952093 genotypes (CC, CA, and 
AA) and allele (C/A) frequency distribution was found 
to have no statistically significant association with thera-
peutic response when compared between non-relapse 
vs relapse (p = 0.538, p = 1.076, p = 1.425 of genotypes 
and p = 0.66 of allele; Table 3). This finding is in concord-
ance with the study of Persico et al. (2008) who studied 
rs12952093 polymorphism in which 34 % NR and 51.1 % 
SVR patients showed CC genotype, 48.8 % NR and 40.2 % 
SVR with CA genotype and 17.3  % NR and 8.7  % SVR 
with AA genotype with (p = 0.006).
Recent study by Zhao et al. (2016), demonstrated a link 
between SOCS3, STAT3 and IFN-α signaling triggered 
by HCV infection and also reporting that STAT3 regula-
tion correlates inversely with SOCS3 induction by IFN-
α, which may be important in better understanding the 
complex interplay between IFN-α and signal molecules 
during HCV infection. As SOCS3 expression is regulated 
by other cell-signaling pathways, in the current study 
we also studied the suggested link of STAT3 and SOCS3 
expression by Zhao et  al. (2016), with reference to IFN 
based therapy in our studied population. The expression 
of STAT3 was down-regulated in NR group (0.89 ± 0.43) 
which is inversely correlated with the expression of 
SOCS3, whereas there was a slight increase in expression 
of STAT3 in SVR group of patients (1.28  ±  0.29). The 
results of STAT3 down-regulated expression are in agree-
ment with studies on HCV infected patients (Stevenson 
et al. 2013; Li et al. 2012; Ryan et al. 2012). The expres-
sion of STAT3 was not affected by the SOCS3 polymor-
phisms, similar to the SOCS3 gene expression.
 It is noteworthy that in present study we were not 
able to establish a link between the.up/down-regulation 
of SOCS3 and STAT3 expression with SOCS3 SNPs to 
predict SVR to a combination of PEG-IFNα and ribavirin 
in chronic hepatitis C genotype 3a infected patients due 
to overall non-significant association of these SNPs in 
HCV patients. The down-regulated expression observed 
in STAT3 gene could be better explained if the full sign-
aling pathways is studied. The molecular mechanisms 
underlying these associations, as well as their diagnostic 
and prognostic significance, are worth further studies. 
To conclude the results, it can be said that genetic factors 
i.e. polymorphisms alone are not involved in response 
to therapy in our local population. But the current study 
has its limitation due to small sample size and collection 
of samples at different time intervals for the analysis of 
SOCS3 and STAT3 gene expression.
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